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DiseaseMammalian mitochondria synthesize a set of thirteen proteins that are essential for energy generation via
oxidative phosphorylation. The genes for all of the factors required for synthesis of the mitochondrially
encoded proteins are located in the nuclear genome. A number of disease-causing mutations have been
identiﬁed in these genes. In this manuscript, we have elucidated the mechanisms of translational failure for
two disease states characterized by lethal mutations in mitochondrial elongation factor Ts (EF-Tsmt) and
elongation factor Tu (EF-Tumt). EF-Tumt delivers the aminoacyl-tRNA (aa-tRNA) to the ribosome during the
elongation phase of protein synthesis. EF-Tsmt regenerates EF-Tumt:GTP from EF-Tumt:GDP. A mutation of EF-
Tsmt (R325W) leads to a two-fold reduction in its ability to stimulate the activity of EF-Tumt in poly(U)-
directed polypeptide chain elongation. This loss of activity is caused by a signiﬁcant reduction in the ability of
EF-Tsmt R325W to bind EF-Tumt, leading to a defect in nucleotide exchange. A mutation of Arg336 to Gln in
EF-Tumt causes infantile encephalopathy caused by defects in mitochondrial translation. EF-Tumt R336Q is as
active as the wild-type protein in polymerization using Escherichia coli 70S ribosomes and E. coli [14C]Phe-
tRNA but is inactive in polymerization with mitochondrial [14C]Phe-tRNA and mitochondrial 55S ribosomes.
The R336Q mutation causes a two-fold decrease in ternary complex formation with E. coli aa-tRNA but
completely inactivates EF-Tumt for binding to mitochondrial aa-tRNA. Clearly the R336Q mutation in EF-Tumt
has a far more drastic effect on its interaction with mitochondrial aa-tRNAs than bacterial aa-tRNAs.tor Tu; EF-Tsmt, mitochondrial
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During protein biosynthesis, elongation factor Tu (EF-Tu) forms a
ternary complex with aminoacyl-tRNA (aa-tRNA) and GTP and
promotes the binding of the aa-tRNA to the A-site of the ribosome
[1]. Following codon:anticodon interactions, an EF-Tu:GDP complex is
released from the ribosome. Elongation factor Ts (EF-Ts) binds to the
EF-Tu:GDP complex and promotes the exchange of GDP for GTP,
regenerating the active EF-Tu:GTP complex [2].
Mammalian mitochondria have a speciﬁc protein biosynthetic
system responsible for the synthesis of thirteen polypeptides of the
respiratory chain complexes. Protein synthesis in this organellerequires elongation factors that correspond to EF-Tu and EF-Ts (EF-
Tumt and EF-Tsmt). Both of these proteins are encoded in the nuclear
genome, synthesized in the cell cytoplasm, and subsequently
imported into the mitochondrion. While mutations in mitochondrial
DNA are well known to cause disease, few mutations have been
identiﬁed in nuclear genes that encode mitochondrial proteins
required for protein biosynthesis in this organelle. Recently, a
mutation in the gene coding for EF-Tsmt (Arg312 to Trp)3 was
reported leading to encephalomyopathy in one patient and hyper-
trophic cardiomyopathy in another [3]. Both patients died at 7 weeks
of age. This mutation is predicted to disrupt important interactions
between EF-Tumt and EF-Tsmt.
EF-Tsmt is a 30.7 kDa protein that consists of an N-terminal domain
and a core domain divided into N- and C-terminal subdomainsper [3], the position identiﬁed as mutated is listed as Arg333. This
s to the residue in isoform 2 of human EF-Tsmt (P-43897-2).
direct experimental evidence for the expression of this isoform.
-43897-1) has been chosen as the canonical sequence. In humans,
orm 1 is in position 312 (R312W). There is direct experimental
1 in the bovine system. The mutation created here is in isoform 1
t and corresponds to residue 325 (R325W). The mature forms of
us EF-Tsmt are over 92% identical.
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contacts. The N-terminal domain and subdomain N of the core of EF-
Tsmt interact directly with the G-domain (domain I) of EF-Tumt, while
subdomain C of the core contacts domain III of EF-Tumt.
Arg325 of EF-Tsmt is highly conserved and is found in most
bacterial and mitochondrial factors [3]. This residue is located in a β-
strand in subdomain C of the core (shown in blue in Fig. 1A and B).
While it does not make direct contact with EF-Tumt, other nearby
residues in this region do so. Molecular modeling has predicted that
the R325W mutation could disrupt the tertiary structure of the
subdomain C of the core, altering its interactions with domain III of EF-
Tumt [3]. Mutations in this region have been shown to reduce the
afﬁnity of EF-Tsmt for EF-Tumt about six to seven-fold [5]. For example,
mutation of His231 to Ala caused a 6-fold decrease in the binding
constant governing the interaction of EF-Tsmt with EF-Tumt. Mutation
of L302 and L303 (shown in orange in Fig. 1B) caused a 7-fold
decrease in the binding constant governing the interaction of EF-Tumt
and EF-Tsmt. We have directly examined the effect of the R325W
mutation by testing the ability of the mutated protein to bind directly
to EF-Tumt and to stimulate its activity in poly(U)-directed
polymerization.
EF-Tumt is a 45.1 kDa protein composed of three domains. Domain
I contains the guanine nucleotide binding site. All three domains are
involved in binding the aa-tRNA [6], while domains I and III interact
with EF-Tsmt. The stable binding of guanine nucleotides and EF-Tsmt to
EF-Tumt are mutually exclusive, allowing EF-Tsmt to serve as a
nucleotide exchange factor for EF-Tumt [7,8].Fig. 1. Structural view of the interaction of EF-Tumt with EF-Tsmt. A. Overall structure of
the EF-Tumt:EF-Tsmt complex (PDB 1XB2). EF-Tumt is shown in red, and EF-Tsmt is
shown in green. EF-Tsmt R325W is highlighted in blue. B. Close-up view of the
interaction of residues near the R325Wmutation. Domain III of EF-Tumt is shown in red,
subdomain C of EF-Tsmt is shown in green, and EF-Tsmt R325W is shown in blue.
Residues known to be important for the interaction of EF-Tsmt with EF-Tumt are shown
as purple (H231) and orange (L302 and L303) sticks [5].A mutation in EF-Tumt, (Arg336 to Gln), was discovered in an
infant with lactic acidosis and fetal encephalopathy [9]. The infant
later died at an age of 14 months. Arg336 of EF-Tumt is located in
domain II of the protein, in a region known to interact with the
acceptor stem of the aa-tRNAs. EF-Tumt R336Q was previously found
to be unable to form a ternary complex with mitochondrial Ser-tRNA
[10]. The mutated factor was also deﬁcient in poly(U)-directed poly
(Phe) synthesis using mitochondrial Phe-tRNA and E. coli 70S
ribosomes. However, no studies were carried out with mitochondrial
ribosomes and mitochondrial elongation factor G1 (EF-G1mt) [10]. In
this manuscript, the activity of the mutated EF-Tumt is examined on
mitochondrial ribosomes, and the effect of the mutation on its ability
to form ternary complexes with several additional mitochondrial aa-
tRNAs has been examined.
2. Materials and methods
2.1. Materials
[14C]phenylalanine and [35S]methionine were purchased from
Perkin Elmer Life Sciences, Inc. E. coli tRNA was obtained from
Boehringer Mannheim. E. coli [14C]Phe-tRNA and the human mito-
chondrial [35S]Met-tRNA transcript were prepared as described
[11,12]. Mitochondrial tRNA was puriﬁed from bovine mitoplasts
using the Qiagen RNA/DNA maxi kit. The tRNAPhe was aminoacylated
using [14C]Phe as described [13]. E. coli ribosomes were puriﬁed from
E. coli W cells; mitochondrial 55S ribosomes, and EF-G1mt were
puriﬁed as described [14,15].
2.2. Cloning, expression, and puriﬁcation of proteins
BMtu/pET24c and BMts/pET24c, the E. coli expression vectors for
C-terminal histidine-tagged bovine EF-Tumt and EF-Tsmt, are de-
scribed in [16,17] and the proteins expressed from them are referred
to as the wild-type (WT) proteins. Expression vectors for the mutant
EF-Tumt (R336Q) and mutant EF-Tsmt (R325W) were constructed by
using the Quik Change site-directed mutagenesis kit (Stratagene). EF-
Tumt and EF-Tsmt were puriﬁed using described protocols [4,16,18].
2.3. Circular dichroism of EF-Tsmt and EF-Tsmt R325W
Puriﬁed EF-Tsmt and EF-Tsmt R325W were dialyzed in 1000
volumes CD buffer containing: 10 mM MgSO4, 50 mM potassium
phosphate buffer (pH 7.6), and 5% glycerol for 4 h with a change of
buffer after 2 h. CD spectra of EF-Tsmt and EF-Tsmt R325W were
obtained using an Aviv Model 62DS Circular Dichroism Spectrometer.
Data points were collected in 1 nm steps, and the data were analyzed
using the CD Pro software.
2.4. Poly(Phe) polymerization assays
To test the ability of EF-Tsmt to stimulate the activity of EF-Tumt in
poly(Phe) directed polymerization, reaction mixtures (25 µL)
contained 50 mM Tris–HCl (pH 7.8), 1 mM dithiothreitol (DTT),
0.1 mM spermine, 6 mM MgCl2, 80 mM KCl, 0.5 mM GTP, 1.25 mM
phospho(enol)pyruvate (PEP), 0.4 U pyruvate kinase, 3 µg poly(U),
8.3 pmol (0.33 µM) E. coli [14C]Phe-tRNA, 5 pmol (0.2 µM) EF-G1mt,
0.25 µM E. coli 70S ribosomes, 0.5 pmol (20 nM) EF-Tumt, and 0.025–
0.075 pmol (1–3 nM) EF-Tsmt. The reaction mixtures were incubated
at 37 °C for 30 min and analyzed as described [19]. A blank
representing the amount of label retained on the ﬁlter in the absence
of EF-Tsmt was not subtracted in order to illustrate the level of
polymerization obtained in the presence of EF-Tumt alone.
To test the poly(Phe) polymerization activity of WT and mutated
EF-Tumt in the E. coli system, reaction mixtures (25 µL) contained
50 mM Tris–HCl (pH 7.8), 1 mM DTT, 0.1 mM spermine, 6 mMMgCl2,
Fig. 2. Circular dichroism spectra of EF-Tsmt and EF-Tsmt R325W. CD spectra of EF-Tsmt
(WT and R325W) obtained as described in Materials and methods.
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poly(U), 8.3 pmol (0.3 µM) E. coli [14C]Phe-tRNA, 5 pmol (0.2 µM) EF-
G1mt, 16 µg (0.25 µM) E. coli 70S ribosomes, and 0.2–0.8 pmol (8–
32 nM) EF-Tumt (WT or R336Q) in a 1:1 mix with EF-Tsmt. Reaction
mixtures were incubated at 37 °C for 30 min, at which time they were
quenched by the addition of 5% TCA and processed as described [19]. A
blank representing the amount of label retained on the ﬁlter in the
absence of EF-Tumt (∼0.3 pmol) was subtracted from each value.
For assays performed in the mitochondrial system, the reaction
mixtures (25 µL) contained 50 mM Tris–HCl (pH 7.8), 1 mM DTT,
0.1 mM spermine, 7.5 mM MgCl2, 40 mM KCl, 0.5 mM GTP, 1.25 mM
PEP, 0.4 U pyruvate kinase, 3 µg poly(U), 3 pmol (0.12 µM) mito-
chondrial [14C]Phe-tRNA, 5 pmol (0.2 µM) EF-G1mt, 3 pmol (0.12 µM)
mitochondrial 55S ribosomes, and 0.2–0.8 pmol EF-Tumt (WT or the
R336Q mutated protein) in a 1:1 mixture with EF-Tsmt. Reactions
were incubated at 37 °C for 30 min, quenched by the addition of 5%
TCA, and processed as described [19]. A blank representing the
amount of label retained on the ﬁlter in the absence of EF-Tumt
(∼0.08 pmol) was subtracted from each value.
2.5. Physical interaction of EF-Tumt and EF-Tsmt measured using
a gel-shift assay
The binding of EF-Tsmt to EF-Tumt was studied using a gel-shift
assay according to [20]. Brieﬂy, EF-Tsmt (40 pmol) and EF-Tumt:GDP
(0–40 pmol) were incubated on ice for 5 min in a reaction mixture
(10 µL ) containing: 50 mM Tris–HCl (pH 7.5), 70 mM KCl, 1.5 mM
EDTA, 10% glycerol, 1 mM DTT, 0.004% bromophenol blue. The
samples were resolved by native polyacrylamide gel electrophoresis
(PAGE). The electrophoresis was performed at 4 °C (450 V, 2 h) on a
1 mm×20 cm×10 cm 9% PAGE gel (acrylamide:bisacrylamide 29:1)
containing 8 mM Tricine–NaOH (pH 8.2), 1 mM EDTA and 5% glycerol.
The running buffer contained 8 mM Tricine–NaOH (pH 8.2) and 1 mM
EDTA. The proteins were visualized using SYPRO Ruby (Molecular
Probes).
2.6. Ternary complex formation measured using hydrolysis protection
The ability of EF-Tumt and EF-Tumt R336Q to protect aa-tRNA from
spontaneous deacylation was monitored as described [21], with slight
modiﬁcations. Ternary complexes were formed in reaction mixtures
(100 µL) containing 75 mM Tris–HCl (pH 7.5), 75 mM NH4Cl, 15 mM
MgCl2, 7.5 mM DTT, 60 µg/ml bovine serum albumin, 1 mM GTP,
2.4 mM PEP, 0.1 U pyruvate kinase, 12.5 pmol (0.125 µM) E. coli [14C]
Phe-tRNA, and 0–330 pmol (0–3.3 µM) EF-Tumt (WT or R336Q). The
samples were incubated for the indicated times at 30 °C, and
precipitated in cold 5% TCA. The remaining aa-tRNA was collected
on ﬁlter papers (3MM,Whatman) and the amount of EF-Tu:GTP:[14C]
Phe-tRNA was quantiﬁed using a liquid scintillation counter.
2.7. Ternary complex formation measured using RNase protection
Ternary complex formation assays were carried out in reaction
mixtures (50 µL) containing 20 mM HEPES–KOH (pH 7.0), 1 mM DTT,
6.7 mMMgCl2, 68 mM KCl, 0.5 mM GTP, 1.25 mM PEP, 0.8 U pyruvate
kinase, 7.2 pmol (0.14 µM) E. coli [14C]Phe-tRNA, and 0–20 pmol (0.1–
0.4 µM) EF-Tumt (WT or R336Q). For experiments using mitochon-
drial tRNAs, 5.3 pmol (0.11 µM) native bovine mitochondrial [14C]
Phe-tRNA or 9.6 pmol (0.19 µM) of the human mitochondrial [35S]
Met-tRNA transcript and 0–60 pmol (0–1.2 µM) EF-Tumt (WT or
R336Q) were used. The reactions were incubated for 15 min at 0 °C, at
which time 10 µg RNase A was allowed to digest the sample for 30 s.
Ice cold 5% TCA was added, and the remaining aa-tRNA was
precipitated at 0 °C for 10 min and analyzed as described [12,22]. A
blank representing the amount of label retained on the ﬁlters in the
absence of EF-Tumt (∼0.3 pmol using E. coli [14C]Phe-tRNA, ∼0.1 pmolusing mitochondrial [14C]Phe-tRNA and ∼0.2 pmol using [35S]Met-
tRNA) was subtracted from each value.
3. Results and discussion
3.1. Biochemical consequences of the R325W mutation in EF-Tsmt
A mutated derivative of bovine EF-Tsmt (R325W) was prepared
using site-directed mutagenesis corresponding to the lethal mutation
in humans [3]. To determine whether the mutation adversely affected
the structure of EF-Tsmt, the CD spectra of the mutated derivative was
compared to that of the WT factor. As indicated in Fig. 2, the α-helical
content of the mutated protein did not change signiﬁcantly with
respect to thewild-type factor, suggesting that the protein retained its
normal secondary structure. A thermal melt monitored by CD
indicated that both EF-Tsmt and EF-Tsmt R325W unfold at the same
temperature (data not shown), indicating that the mutation has not
greatly destabilized the protein.
To investigate the biochemical effect of the R325W mutation, the
ability of EF-Tsmt and its R325W variant to stimulate the activity of EF-
Tumt in poly(Phe) polymerization was examined. EF-Tumt alone has
measurable activity in polymerization, as indicated by the consider-
able amount of Phe polymerized in the absence of EF-Tsmt (Fig. 3, y-
intercept). However, its activity is enhanced by the presence of EF-
Tsmt due to an increase in the guanine nucleotide exchange rate,
allowing EF-Tumt to be used more catalytically. Wild-type EF-Tsmt
stimulated the activity of EF-Tumt more than 2-fold under the reaction
conditions used (Fig. 3). This value is consistent with previous
observations [23]. However, the stimulation of EF-Tumt by the R325W
variant was reduced substantially, and only a 1.2-fold stimulation was
observed (Fig. 3). This reduction could arise from the failure of the
mutated EF-Tsmt to interact with EF-Tumt:GDP effectively, reducing
GDP release and formation of an EF-Tumt:EF-Tsmt complex. The
reduction could also reﬂect a failure of the EF-Tumt:EF-Tsmt complex
to bind GTP, which is necessary to release EF-Tumt for another round
of polymerization.
To investigate the interaction between EF-Tumt and EF-Tsmt
R325W directly, the binding of the two proteins was studied using a
gel-shift assay (Fig. 4). EF-Tsmt or EF-Tsmt R325Wwas incubated with
increasing amounts of EF-Tumt. After complex formation, the proteins
were separated on native-PAGE. This gel system separates EF-Tsmt
from the EF-Tumt:EF-Tsmt complex. However, the mobility of EF-Tumt:
EF-Tsmt complex was quite similar to that for EF-Tumt, and the
resolution of the complex from free EF-Tumt was difﬁcult. Thus, the
efﬁciency of complex formation was assessed by the quantity of free
EF-Tsmt remaining. Wild-type EF-Tsmt was effective in forming a
complex with EF-Tumt in a dose dependent manner. Approximately
Fig. 3. Activity of EF-Tsmt and EF-Tsmt R325W in poly(Phe) polymerization. The abilities
of EF-Tsmt and EF-Tsmt R325W to function in a poly(U)-directed peptide polymerization
assay were tested using EF-Tumt and E. coli [14C]Phe-tRNA. EF-Tsmt is shown in closed
squares and EF-Tsmt R325W is shown in closed circles. The assays were performed
multiple times and data were normalized with respect to the point containing
0.05 pmol of EF-Tsmt.
Fig. 4. Physical interaction of EF-Tsmt and EF-Tsmt R325W with EF-Tumt. The abilities of
EF-Tsmt and EF-Tsmt R325W to bind to EF-Tumt weremeasured using a gel-shift assay on
native-PAGE. A. WT EF-Tsmt (upper panel) or EF-Tsmt R325W (lower panel) were
incubated with the indicated amount of EF-Tumt. The proteins were separated on
native-PAGE and visualized by SYPRO Ruby. The position of EF-Tsmt, EF-Tumt:EF-Tsmt
complex and EF-Tumt are indicated with arrows. B. The efﬁciency of the complex
formation in A was assessed by the amount of free EF-Tsmt remaining. The relative
amount of free EF-Tsmt in each panel was normalized to a value of 1 for EF-Tsmt. EF-Tsmt
is shown in closed circles, and EF-Tsmt R325W is shown in closed squares.
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equal molar amounts of the two factors (Fig. 4A, upper panel and
Fig. 4B, closed circles). In contrast, EF-Tsmt R325W was ineffective in
binding EF-Tumt and remained free, even when incubated with an
equal amount of EF-Tumt (Fig. 4A, lower panel and Fig. 4B, closed
squares). These results indicate that the reduction in poly(U)-
dependent poly(Phe) synthesis with the mutated EF-Tsmt arises to a
large extent from a failure of the mutated EF-Tsmt to interact with EF-
Tumt.
The effect observed with the R325 mutation is in agreement with
previous mutational data as described in the Introduction. The data
provided here and the mutational studies carried out previously
indicate that the interactions of residues in the β-sheet of subdomain
C and other nearby residues with EF-Tumt are essential for the stable
binding of EF-Tumt with EF-Tsmt.
3.2. Biochemical consequences of the R336Q mutation in EF-Tumt
Arg336 in EF-Tumt is located in domain II in a pocket where the 5′
end of the aa-tRNA is bound. The adjacent residue (Arg335) in EF-Tumt
was previously found to be important for the activity of EF-Tumt in
both ternary complex formation and A-site binding with mitochon-
drial Phe-tRNAPhe [22]. Previous work on the lethal R336Qmutation in
EF-Tumt indicated that this mutation did not affect the structural
integrity of EF-Tumt, as demonstrated by CD spectroscopy [10].
However, the mutation drastically reduced the ability of EF-Tumt to
promote polymerization using mitochondrial [14C]Phe-tRNA on E. coli
ribosomes [10]. The R336Q mutation was not predicted to inﬂuence
the interaction of EF-Tumt with EF-Tsmt, because the primary
interaction with EF-Tsmt occurs via interactions involving domains I
and III [4]. The mutation was also not expected to interfere with GTP
binding, which is localized to domain I.
The effects of the R336Q mutation on the activity of EF-Tumt were
examined further using E. coli and mitochondrial ribosomes and aa-
tRNAs. Surprisingly, when EF-Tumt R336Q was tested in poly(U)-
directed polymerization using E. coli [14C]Phe-tRNA and E. coli 70S
ribosomes, it was as active as the wild-type factor in this assay
(Fig. 5A). However, in the homologous system using mitochondrial
[14C]Phe-tRNA and ribosomes, EF-Tumt R336Q was almost inactive in
polypeptide chain elongation (Fig. 5B). Previous work [10] indicated
that EF-Tumt R336Q lacked activity with mitochondrial [14C]Phe-tRNA
when tested on E. coli ribosomes, suggesting that the lack of activity in
the mitochondrial system was not a function of the ribosomes used
but, rather, due to a failure of the mutated factor to interact with
mitochondrial Phe-tRNA. Mitochondrial tRNAs are less structurally
stable than E. coli tRNAs [12], and additional stabilizing interactions
between EF-Tumt and the mitochondrial aa-tRNAmay be important in
forming the ternary complex.
The poly(Phe) polymerization assay does not directly measure the
interaction between EF-Tumt and aa-tRNA. This interaction can be
measured directly using one of two ternary complex formation
assays: the hydrolysis protection assay and the RNase protection
assay. The hydrolysis protection assay measures the ability of EF-Tumt
to protect the aa-tRNA bond from spontaneous hydrolysis. Since the
mutated EF-Tumt was active using E. coli Phe-tRNA in polymerization,
its interaction with bacterial Phe-tRNA was tested directly. The
spontaneous hydrolysis of E. coli Phe-tRNA was apparent (Fig. 6A,
closed circles). When bound to EF-Tumt, the Phe-tRNA bond was
clearly protected from hydrolysis (Fig. 6A, solid lines). However, when
the R336Q derivative of EF-Tumt was used in place of the normal
factor, substantially less protection of the Phe-tRNA bond was
observed (Fig. 6A, dashed lines). At sufﬁciently high concentrations
of EF-Tumt R336Q, a considerable number of ternary complexes were
formed (Fig. 6B, closed squares), indicating that R336Q has some
ability to bind E. coli Phe-tRNA. This data suggests that, although the
mutated protein is deﬁcient in binding to E. coli Phe-tRNA, the
Fig. 5. Poly(Phe) polymerization with EF-Tumt and EF-Tumt R336Q. The abilities of EF-
Tumt and its R336Q derivative to function in a poly(Phe) polymerization assay was
tested as described in Materials and methods. A. Poly(Phe) polymerization assay using
E. coli 70S ribosomes and E. coli [14C]Phe-tRNA. EF-Tumt is shown in closed circles and
EF-Tumt R336Q in closed squares. B. Poly(Phe) polymerization assay using mitochon-
drial 55S ribosomes and native bovine mitochondrial [14C]Phe-tRNA. EF-Tumt is shown
in closed circles and EF-Tumt R336Q is shown in closed squares.
Fig. 6. Activities of EF-Tumt and EF-Tumt R336Q in ternary complex formation measured
using a non-enzymatic hydrolysis protection assay. A. Amount of [14C]Phe-tRNA
protected from hydrolysis by increasing concentrations of EF-Tumt (solid lines) and EF-
Tumt R336Q (dashed lines) as a function of time. B. Relative amount of [14C]Phe-tRNA at
time 60 min in Fig. 5A is plotted against the EF-Tumt concentration.
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polymerization (Fig. 5).
To verify the results obtained from the hydrolysis protection
experiments and to examine the interaction with mitochondrial aa-
tRNAs, the RNase protection assay was used. This assay measures the
ability of EF-Tumt to protect the acceptor stem of the aa-tRNA from
degradation by RNase A. Because the RNase A digestion of the tRNA is
done in 30 s, it provides a snapshot of the interaction between the two
molecules. When the binding of EF-Tumt to E. coli [14C]Phe-tRNA was
tested, the R336Q variant showed a decrease in binding of just over
50% (Fig. 7A), indicating that the mutation reduces but does not
abolish the ability of EF-Tumt to form a ternary complex with bacterial
aa-tRNAs. These results agree with the observation above, that the
reduction in ternary complex formation observed is not sufﬁcient to
compromise the activity of this factor in polymerization (Fig. 5). It is
important to note that the binding of the aa-tRNA to EF-Tumt is
probably not the rate limiting step in polypeptide chain elongation.
Rather, interactions with the ribosome, including the release of
inorganic phosphate from EF-Tumt following GTP hydrolysis, appear
to be rate limiting [24].
Previous work indicated that EF-Tumt R336Q did not bind
mitochondrial Ser-tRNA effectively in the ternary complex [10]. This
observation is in sharp contrast to the signiﬁcant level of ternary
complex formation observed with the E. coli Phe-tRNA (Fig. 6) but in
agreement with the lack of polymerization observed with mitochon-drial Phe-tRNA (Fig. 5). To explore whether the failure of EF-Tumt to
use mitochondrial Phe-tRNA in polymerization arises from a failure of
ternary complex formation, the RNase protection assay was carried
out with mitochondrial [14C]Phe-tRNA (Fig. 7B). EF-Tumt was quite
active in forming a ternary complex with native bovine mitochondrial
Phe-tRNA. However, the R336Q variant did not bind mitochondrial
Phe-tRNA detectably (Fig. 7B). This observation agrees with previous
work and explains the lack of activity of the mutated protein in poly
(Phe)-directed polymerization with mitochondrial Phe-tRNA on
mitochondrial 55S ribosomes (Fig. 5).
To address the question of whether other mitochondrial aa-tRNAs
also fail to bind the R336Q variant, ternary complex formation assays
were carried out using human mitochondrial [35S]Met-tRNA (Fig. 6C).
This tRNA was transcribed in vitro and has been shown to fold
properly and to bind EF-Tumt [12]. In this assay, EF-Tumt readily
formed a ternary complex with mitochondrial [35S]Met-tRNA.
However, once again EF-Tumt R336Q was unable to bind mitochon-
drial [35S]Met-tRNA, indicating that the mutated protein is probably
unable to form ternary complexes with most or all mitochondrial aa-
tRNAs.
It is perplexing that the mutated variant of EF-Tumt can bind E. coli
Phe-tRNA but not mitochondrial aa-tRNAs. This discrepancy must
stem from the innate differences between the mitochondrial and
bacterial tRNAs. Canonical tRNAs fold into a distinct L-shape stabilized
by strong G–C base pairs in the stems of the tRNA and tertiary
interactions involving many invariant or semi-invariant residues [25].
In contrast, mitochondrial tRNAs are characterized by weaker stems
Fig. 7. Activities of EF-Tumt and EF-Tumt R336Q in ternary complex formation measured
using an RNase protection assay. EF-Tumt is shown in closed circles and EF-Tumt R336Q
is shown in closed squares. A. Ternary complex formation using E. coli [14C]Phe-tRNA.
B. Ternary complex formation with native bovine mitochondrial [14C]Phe-tRNA.
C. Ternary complex formation using human mitochondrial [35S]Met-tRNA.
Fig. 8. Interaction of T. thermophilus EF-Tu with aa-tRNA. This image was obtained from
the crystal structure of the T. thermophilus Phe-tRNA:EF-Tu:GDPNP ternary complex
(PDB 1TTT). The residue homologous to R336 is shown with its nitrogen atoms in blue.
The phosphate of G1 of the Phe-tRNA is shown in orange, with its oxygen atoms shown
in red. The tRNA is shown in dark gray.
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conserved residues that create important tertiary interactions in other
tRNAs [26–28]. Although mitochondrial tRNAs can fold into an L-
shape, the interactions that stabilize the elbow region are weaker [29].
Mitochondrial tRNAs observed on 55S ribosomes have an L-shape but
show a “caved in” feature at the corner of the L [29]. These unusual
structural features of mitochondrial tRNAs may lead to a requirement
for interactions with EF-Tumt that are not essential for the binding of
canonical aa-tRNAs.Previous data indicate that mitochondrial aa-tRNAs must be
phosphorylated at their 5′ ends in order to bind effectively to EF-
Tumt [12]. The crystal structure of the Thermus thermophilus ternary
complex indicates that Arg300 (corresponding to Arg336 in EF-Tumt)
forms a salt bridge with the phosphate group at the 5′ end of the aa-
tRNA (Fig. 8) [6]. Replacement of the Arg with Gln in the mutated EF-
Tumt could disrupt this interaction, since the side chain of Gln is
shorter and may not be within bridging distance of the phosphate
backbone. This interaction is not critical for the formation of the
ternary complex with E. coli aa-tRNAs, in agreement with data
showing that a 5′-phosphate is not important for ternary complex
formation in prokaryotes [30]. However, the data presented here
indicate that the interaction between Arg336 and the 5′ phosphate of
mitochondrial aa-tRNAs is critical for ternary complex formation in
the mitochondrial translational system. The interaction between
Arg336 and the 5′ phosphate of aa-tRNAs could also be important
following ternary complex formation, since the aa-tRNA in the ternary
complex is substantially distorted upon the ribosome binding,
allowing it to interact simultaneously with the mRNA codon and the
EF-Tumt [31].
4. Conclusions
Numerous mutations in mitochondrial tRNAs and rRNAs have
been reported that lead to diseases such as Myoclonic Epilepsy and
Ragged Red Muscle Fibers (MERRF), and Leber Hereditary Optic
Neuropathy (LHON), and Leigh Syndrome (Mitomap). However,
mutations in nuclear-encoded proteins required for the translation
of mitochondrial mRNAs are rarer. In addition to the mutations in EF-
Tumt and EF-Tsmt investigated in this report, several other mutations
in proteins involved in mitochondrial translation have been reported.
Lethal mutations of mitochondrial elongation factor G1 were
discovered in a patient with had lactic acidosis, fatal encephalopathy,
and early-onset Leigh syndrome [9]. An additional mutation was
previously reported in the coding sequence for EF-G1 that led to
deﬁciencies in oxidative phosphorylation and to liver dysfunction
[32]. A fatal mutation in mitochondrial small ribosomal protein
MRPS16 was found in a patient with neonatal lactic acidosis [33], and
a mutation in the small subunit ribosomal protein MRPS22 was also
lethal [34]. Both ribosomal protein mutations lead to defects in the
assembly of the small subunit [35].
In this paper, we have analyzed the mechanisms by which
mutations in two elongation factors (EF-Tumt and EF-Tsmt) cause
fatal defects in mitochondrial translation. Oxidative phosphorylation
requires the assembly of the electron transport chain and ATP
698 K. Akama et al. / Biochimica et Biophysica Acta 1802 (2010) 692–698synthase, which contain protein components synthesized by the
mitochondrial translational machinery. A defect in mitochondrial
translation caused by the inability of EF-Tsmt R325Q to bind to EF-Tumt
likely leads to the defects in oxidative phosphorylation seen in the
clinical manifestation of the EF-Tsmt mutation.
The R336Q variant of EF-Tumt is inactive in mitochondrial
polypeptide chain elongation as a result of its inability to bind
mitochondrial aa-tRNAs. Failure of ternary complex formation leads
to defective mitochondrial protein synthesis, causing a decrease in
oxidative phosphorylation. One direct clinical phenotype of the EF-
Tumt R336Q mutation is lactic acidosis [9], which most likely resulted
from the buildup of lactic acid from pyruvate due to a failure in the
synthesis of the respiratory chain.
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